|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11458091||INDIVIOR||Compositions and methods for the treatment of opioid overdose|| |
(14 years from now)
Opvee is owned by Indivior.
Opvee contains Nalmefene Hydrochloride.
Opvee has a total of 1 drug patent out of which 0 drug patents have expired.
Opvee was authorised for market use on 22 May, 2023.
Opvee is available in spray;nasal dosage forms.
Opvee can be used as treating opioid overdose.
The generics of Opvee are possible to be released after 10 July, 2038.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Product (NP)||May 22, 2026|
Market Authorisation Date: 22 May, 2023
Treatment: Treating opioid overdose